Methods Study design This trial was an investigator-initiated, single-center, open-label, randomized, parallel group study conducted at Daping Hospital, ChongQing, China between August 1 st, 2023, and March 1 st, 2024
Primary source for contraindications and warnings, used for the FAQ in Section 10
This is difficult due to the cost, as well as disagreement between experts on evaluation and remediation
Most adverse effects can be minimised through practical strategies and appropriate clinical monitoring
The research also did not examine varying dosages or fully compare all the types of GLP-1 drugs